Condition: Malignant Melanoma · Sponsor: Merck Sharp & Dohme LLC
Researchers want to learn if intismeran autogene with pembrolizumab can stop advanced melanoma from growing or spreading. Melanoma is a type of skin cancer. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. A standard (or usual) treatment for advanced melanoma is immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Intismeran autogene is a study treatment designed to help a person's immune system attack their specific cancer. Pembrolizumab is an immunotherapy. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab live longer without the cancer growing or spreading than people who receive placebo with pembrolizumab. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group ( Site 4042) | Springdale, Arkansas, United States | Recruiting |
| UCSF Medical Center at Mission Bay ( Site 4044) | San Francisco, California, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047) | Hackensack, New Jersey, United States | Recruiting |
| Inova Schar Cancer Institute ( Site 4046) | Fairfax, Virginia, United States | Recruiting |
| Fred Hutchinson Cancer Center ( Site 4041) | Seattle, Washington, United States | Recruiting |
| Blacktown Hospital ( Site 2001) | Blacktown, New South Wales, Australia | Recruiting |
| Melanoma Institute Australia ( Site 2000) | Wollstonecraft, New South Wales, Australia | Recruiting |
| One Clinical Research ( Site 2002) | Nedlands, Western Australia, Australia | Recruiting |
| William Osler Health System (Brampton Civic Hospital) ( Site 2023) | Brampton, Ontario, Canada | Recruiting |
| Sunnybrook Research Institute ( Site 2022) | Toronto, Ontario, Canada | Recruiting |
| Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2042) | Nice, Alpes-Maritimes, France | Recruiting |
| Hôpital Saint-Louis ( Site 2041) | Paris, Île-de-France Region, France | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06961006